臨床泌尿器科68巻11号

2014年10月発行

特集 泌尿器科医のためのクリニカル・パール（1）

膀胱癌のクリニカル・パール

著者： 北村寛¹

所属機関： ¹札幌医科大学医学部泌尿器科学講座

ページ範囲：P.838 - P.842

要旨　膀胱癌の領域では久しく新薬は登場しておらず，ほかの癌種に比べて治療開発が遅れている感が否めない。したがって，泌尿器科医は限られたエビデンスの中から，患者に最良の医療を提供しなければならない。本稿ではTURBT（transurethral resection of bladder tumor）時の筋層採取の重要性，BCG（bacillus Calmette-Guérin）failure例の取り扱い，膀胱全摘除術の実施時期，ネオアジュバント化学療法の有用性，リンパ節郭清の至適範囲，および膀胱全摘除術に注意すべきポイントをクリニカル・パールとして取り上げ，概説した。

参考文献

1）Babjuk M, Böhle A, Burger M, et al：Guidelines on non-muscle-invasive bladder cancer（Ta, T1 and CIS）. European Association of Urology, 2014

2）Divrik RT, Sahin AF, Yildirim Ü, et al：Impact of routine second transurethral resection on the long-term outcome of patients with newly diagnosed pT1 urothelial carcinoma with respect to recurrence, progression rate, and disease-specific survival：a prospective randomised clinical trial. Eur Urol 58：185-190, 2010

3）Shindo T, Masumori N, Kitamura H, et al：Clinical significance of definite muscle layer in TUR specimen for evaluating progression rate in T1G3 bladder cancer：multicenter retrospective study by the Sapporo Medical University Urologic Oncology Consortium（SUOC）. World J Urol［Epub ahead of print］

4）Yates DR, Brausi MA, Catto JWF, et al：Treatment options available for bacillus Calmette-Guérin failure in non-muscle-invasive bladder cancer. Eur Urol 62：1088-1096, 2012

5）Huguet J, Crego M, Sabaté S, et al：Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy：pre-cystectomy prostate involvement as a prognostic factor. Eur Urol 48：53-59, 2005

6）Nieder AM, Brausi M, Lamm D, et al：Management of stage T1 tumors of the bladder：international consensus panel. Urology 66（Suppl 6 A）：108-125, 2005

7）Shirakawa H, Kikuchi E, Tanaka N, et al：Prognostic significance of bacillus Calmette-Guérin failure classification in non-muscle-invasive bladder cancer. BJU Int 110：E216-221, 2012

8）Takahashi A, Tsukamoto T, Tobisu K, et al：Radical cystectomy for invasive bladder cancer：results of multi-institutional pooled analysis. Jpn J Clin Oncol 34：14-19, 2004

9）Hara I, Miyake H, Hara S, et al：Optimal timing of radical cystectomy for patients with invasive transitional cell carcinoma of the bladder. Jpn J Clin Oncol 32：14-18, 2002

10）Sánchez-Ortiz RF, Huang WC, Mick R, et al：An interval longer than 12 weeks between the diagnosis of muscle invasion and cystectomy is associated with worse outcome in bladder carcinoma. J Urol 169：110-115, 2003

11）Chang SS, Hassan JM, Cookson MS, et al：Delaying cystectomy for muscle invasive bladder cancer results in worse pathological stage. J Urol 170：1085-1087, 2003

12）May M, Nitzke T, Helke C, et al：Significance of the time period between diagnosis of muscle invasion and radical cystectomy with regard to the prognosis of transitional cell carcinoma of the urothelium in the bladder. Scand J Urol Nephrol 38：231-235, 2004

13）Mahmud SM, Fong B, Fahmy N, et al：Effect of preoperative delay on survival in patients with bladder cancer undergoing cystectomy in Quebec：a population based study. J Urol 175：78-83, 2006

14）Lee CT, Madii R, Daignault S, et al：Cystectomy delay more than 3 months from initial bladder cancer diagnosis results in decreased disease specific and overall survival. J Urol 175：1262-1267, 2006

15）Gore JL, Lai J, Setodji CM, et al：Mortality increases when radical cystectomy is delayed more than 12 weeks. Results from a Surveillance, Epidemiology, and End Results-Medicare analysis. Cancer 115：988-996, 2009

16）Grossman HB, Natale RB, Tangen CM, et al：Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 349：859-866, 2003

17）International Collaboration of Trialists on behalf of the Medical Research Council Advanced Bladder Cancer Working Party（now the National Cancer Research Institute Bladder Cancer Clinical Studies Group）, the European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group, the Australian Bladder Cancer Study Group, et al：International phase Ⅲ trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer：long-term results of the BA06 30894 trial. J Clin Oncol 29：2171-2177, 2011

18）Advanced Bladder Cancer（ABC）Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer：Update of a systematic review and meta-analysis of individual patient data. Eur Urol 48：202-206, 2005

19）Zaid HB, Patel SG, Stimson CJ, et al：Trends in the utilization of neoadjuvant chemotherapy in muscle-invasive bladder cancer：results from the National Cancer Database. Urology 83：75-80, 2014

20）Kitamura H, Tsukamoto T, Shibata T, et al：Randomised phase Ⅲ study of neoadjuvant chemotherapy with methotrexate, doxorubicin, vinblastine and cisplatin followed by radical cystectomy compared with radical cystectomy alone for muscle-invasive bladder cancer：Japan Clinical Oncology Group Study JCOG0209. Ann Oncol 25：1192-1198, 2014

21）Herr H：Extent of surgery and pathology evaluation has an impact on bladder cancer outcomes after radical cystectomy. Urology 61：105-108, 2003

22）Kitamura H, Takei F, Nishida S, et al：Lymph node metastasis mapping in extended lymphadenectomy to the level of the inferior mesenteric artery for bladder cancer. Int J Clin Oncol 17：63-68, 2012

23）Kitamura H, Masumori N, Tsukamoto T：Role of lymph node dissection in management of bladder cancer. Int J Clin Oncol 16：179-185, 2011

24）Leissner J, Ghoneim MA, Abol-Enein Hm et al：Extended radical lymphadenectomy in patients with urothelial bladder cancer：results of a prospective multicenter study. J Urol 171：139-144, 2004

25）Zehnder P, Studer UE, Skinner EC, et al：Super extended versus extended pelvic lymph node dissection in patients undergoing radical cystectomy for bladder cancer：a comparative study. J Urol 186：1261-1268, 2011

26）Dangle PP, Gong MC, Bahnson RR, et al：How do commonly performed lymphadenectomy templates influence bladder cancer nodal stage? J Urol 183：499-504, 2010